Download now Free registration required
Allison Lawton, Senior Vice President of Regulatory Affairs at Public Policy at Genzyme Corporation, reviews the importance of drug safety concerns as a catalyst for transparency in biopharma. She then gives a glimpse, from the perspective of someone within the pharmaceutical industry, into the challenges of meeting the public demand for increased - yet objective and useful - information. Lawton also discusses the changes future leaders in the health and medical sectors will have to make to both meet the challenges, and reap the benefits, of greater transparency.
- Format: Webcast
- Size: 0 KB